NY-TINYPASS/PIANO-MEDIA
11.8.2015 14:31:48 CEST | Business Wire | Pressemeddelelse
Tinypass and Piano Media, two pioneers in content monetization and paywall software, announced a merger today to create Piano, a SaaS company specializing in advanced media business processes and online commerce optimization software. The new firm will be led by Chief Executive Trevor Kaufman, previously CEO of Tinypass. The deal reflects a global move by media businesses to paid models for digital content and the need for comprehensive monetization, intelligence and analytics tools to support these efforts.
“Digital media businesses are increasingly focused on monetizing their loyal users,” said Kaufman. “Joining Tinypass with Piano Media to form Piano and globally standardizing on our new VX platform will provide publishers and media companies with the most effective and usable monetization and analytics tools available.”
Piano’s industry-leading VX software is based on a value exchange model that uses big data to segment audience and present user’s different monetization options based on their individual profiles. “It’s obvious to everyone in our industry that the display-advertising-only model for content is broken,” Kaufman said. “Combining Piano Media and Tinypass puts us in an incredible position, not only to continue to address the fundamental software challenges faced by the media business – like managing users, getting good data, and tracking entitlements across the web, apps, and traditional media – but to help them innovate entirely new models as well.”
In addition to providing media companies with the capacity to seamlessly implement a virtually limitless array of pay and subscription models, Piano offers advanced data and CRM capabilities to help content companies identify and segment their audience, enabling business models targeted to the individual user. Piano’s platform integrates easily alongside existing advertising solutions, allowing clients to optimize their mix of paid and ad-supported media.
Piano clients include NBC Universal, Time Inc., The McClatchy Company, The EW Scripps Company, The Post Media Company, News Corp. and IBT Media. Recent launches have included CNBC’s Pro, the premium OTT streams of the Tour de France and Real Simple magazine. Additionally, more than 1,200 other news and media providers around the world, both Omni-channel and digital only, depend on Piano’s SaaS platform to manage their paid content and subscription offerings across the web, apps and physical media.
Kelly Leach, Piano Media’s former CEO, who will be serving as a senior adviser to the company and joining Piano’s board added, “Audience intelligence and optimization are critical elements of content monetization. By joining forces, the combined company is able to offer media companies the most comprehensive, effective and user-friendly platform in the industry. We look to forward this next chapter in our development.”
The deal follows several months of discussions between Tinypass and Piano Media and is effective immediately.
Piano is headquartered at One World Trade Center in New York, with European offices in Slovakia, Austria and Poland and a development office in Russia.
About Piano
Piano, headquartered in New York City, is a leading provider of metering and paywall solutions for digital content monetization and media user data analysis. Newspaper publishers using Piano SaaS software include: News Corp., The McClatchy Company, M. DuMont Schauberg, Postmedia Network Inc., Verlagsgruppe Passau, Digital First Media, DC Thomson, Agora S.A. and Romanes Media Group. Magazine publishers using Piano SaaS software include: Time Inc., Slate, Newsweek and Science Magazine. Broadcasters include: CNBC, NBC Sports and Cox. B2B publishers include: Greentech Media, Intellinews and Business New Europe. For more details see piano.io .
View source version on businesswire.com: http://www.businesswire.com/news/home/20150811005722/en/
Contact:
Harmonica / Conversion Logic
Katy Saeger, +1 310-597-2337
katy@harmonica.co
or
Peter
Epstein, +1 323-251-3567
peter@harmonica.co
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum